CAFVP                                                  breast(19)
 _________________________________________________________________
  cytoxan......... 2 mg/kg orally days 1 to 14, then 100 mg daily.
  adriamycin...... 20 mg/sqm IV day 1, then every 2 weeks.
  fluorouracil.... 12 mg/kg IV days 1 to 3, then every 2 weeks.
  vincristine..... 25 ug/kg IV day 1, then every 2 weeks times 3, 
                   then every 4 weeks.
  prednisone...... 0.75 mg/kg orally days 1 to 14, then 10 mg 
                   daily.
  FREQUENCY....... See drug schedules, above.


  reference...
    Muss HB.  White DR.  Richards F 2d.  Cooper MR.  Stuart JJ. 
    Jackson DV.  Rhyne L.  Spurr CL. Adriamycin versus 
    methotrexate in five-drug combination chemotherapy for 
    advanced breast cancer: a randomized trial. Cancer.  
    42(5):2141-8, 1978 Nov. 
  abstract...
    Adriamycin is of noteworthy efficacy in the treatment of 
    metastatic breast cancer. Its role in combination regimens is 
    under investigation. One hundred seventy-five women with 
    advanced breast cancer were entered into a prospectively 
    randomized trial comparing two five-drug regimens. Regimen 
    CMFVP consisted of cyclophosphamide (C), methotrexate (M), 
    5-fluorouracil (F), vincristine (V), and prednisone (P). 
    Regimen CAFVP was identical but substituted Adriamycin (A) for 
    methotrexate. Twenty-seven patients were disqualified; 148 
    were evaluable. With CMFVP the complete response rate (CR) was 
    11%, and the partial response rate (PR) was 46%; with CAFVP, 
    CR was 13% and PR was 45%. Duration of response tended to be 
    slightly longer for patients on the Adriamycin arm. The median 
    survival for CR and PR patients with CMFVP was 20.2 months, 
    which was shorter (p = .07) than the 33 month median survival 
    with CAFVP. Although statistical significance was not reached 
    at the 5% level, the increased survival of responders on the 
    Adriamycin regimen supports the data of other studies which 
    suggest that first line combination chemotherapy in advanced 
    breast cancer should include Adriamycin.